Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
Citations Over TimeTop 1% of 2014 papers
Abstract
Protein-polymer conjugates are widely used as therapeutics. All Food and Drug Administration (FDA)-approved protein conjugates are covalently linked to poly(ethylene glycol) (PEG). These PEGylated drugs have longer half-lives in the bloodstream, leading to less frequent dosing, which is a significant advantage for patients. However, there are some potential drawbacks to PEG that are driving the development of alternatives. Polymers that display enhanced pharmacokinetic properties along with additional advantages such as improved stability or degradability will be important to advance the field of protein therapeutics. This perspective presents a summary of protein-PEG conjugates for therapeutic use and alternative technologies in various stages of development as well as suggestions for future directions. Established methods of producing protein-PEG conjugates and new approaches utilizing controlled radical polymerization are also covered.
Related Papers
- → Peptide and protein PEGylation(2001)1,048 cited
- → Application of microchip CGE for the analysis of PEG‐modified recombinant human granulocyte‐colony stimulating factors(2010)16 cited
- → PEGylated Antibodies and DNA in Organic Media and Genetic PEGylation(2013)1 cited
- Gene silencing efficiency of siRNA-PEG conjugates : effect of PEGylation site and PEG molecular weight = PEGylation site와 PEG 분자량이 siRNA-PEG conjugate의 유전자 발현 억제에 미치는 영향에 관한 연구(2010)
- → Author Index for Volume 376, Number 1(2000)